Elsa Arbajian

958 total citations
19 papers, 525 citations indexed

About

Elsa Arbajian is a scholar working on Pulmonary and Respiratory Medicine, Rheumatology and Molecular Biology. According to data from OpenAlex, Elsa Arbajian has authored 19 papers receiving a total of 525 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 8 papers in Rheumatology and 6 papers in Molecular Biology. Recurrent topics in Elsa Arbajian's work include Sarcoma Diagnosis and Treatment (10 papers), Soft tissue tumor case studies (4 papers) and Vascular Tumors and Angiosarcomas (3 papers). Elsa Arbajian is often cited by papers focused on Sarcoma Diagnosis and Treatment (10 papers), Soft tissue tumor case studies (4 papers) and Vascular Tumors and Angiosarcomas (3 papers). Elsa Arbajian collaborates with scholars based in Sweden, United States and United Kingdom. Elsa Arbajian's co-authors include Fredrik Mertens, Linda Magnusson, Florian Puls, Vaiyapuri P. Sumathi, Jenny Nilsson, Lars‐Gunnar Kindblom, Jakob Hofvander, Karolin H. Nord, Fredrik Vult von Steyern and Johnbosco Tayebwa and has published in prestigious journals such as Nature Communications, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Elsa Arbajian

18 papers receiving 523 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elsa Arbajian Sweden 14 387 280 154 96 81 19 525
Jakob Hofvander Sweden 14 402 1.0× 245 0.9× 157 1.0× 109 1.1× 122 1.5× 19 532
Anthony P. Martinez United States 11 302 0.8× 195 0.7× 127 0.8× 162 1.7× 36 0.4× 26 470
Salvatore Provenzano Italy 10 295 0.8× 201 0.7× 191 1.2× 62 0.6× 39 0.5× 41 461
Johnbosco Tayebwa Sweden 12 511 1.3× 380 1.4× 256 1.7× 121 1.3× 114 1.4× 12 764
Michał Wągrodzki Poland 14 395 1.0× 218 0.8× 221 1.4× 33 0.3× 59 0.7× 40 510
Takahiro Tajino Japan 15 394 1.0× 343 1.2× 109 0.7× 97 1.0× 91 1.1× 35 641
Dominique Ranchere‐Vince France 8 440 1.1× 140 0.5× 189 1.2× 133 1.4× 136 1.7× 9 524
Alison L. Cheah Australia 10 254 0.7× 169 0.6× 125 0.8× 101 1.1× 38 0.5× 20 348
Ken-ichi Kawaguchi Japan 14 344 0.9× 122 0.4× 180 1.2× 109 1.1× 184 2.3× 20 573
Suk Wai Lam Netherlands 11 216 0.6× 147 0.5× 76 0.5× 54 0.6× 54 0.7× 20 317

Countries citing papers authored by Elsa Arbajian

Since Specialization
Citations

This map shows the geographic impact of Elsa Arbajian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elsa Arbajian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elsa Arbajian more than expected).

Fields of papers citing papers by Elsa Arbajian

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elsa Arbajian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elsa Arbajian. The network helps show where Elsa Arbajian may publish in the future.

Co-authorship network of co-authors of Elsa Arbajian

This figure shows the co-authorship network connecting the top 25 collaborators of Elsa Arbajian. A scholar is included among the top collaborators of Elsa Arbajian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elsa Arbajian. Elsa Arbajian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Staaf, Johan, Hans Brunnström, Mats Jönsson, et al.. (2025). Multi‐omic profiling of squamous cell lung cancer identifies metabolites and related genes associated with squamous cell carcinoma. Molecular Oncology. 19(12). 3806–3820.
2.
Ehmsen, Sidse, Sofie Traynor, N I Nissen, et al.. (2025). RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer. Frontiers in Oncology. 14. 1497093–1497093. 1 indexed citations
3.
Aine, Mattias, Elsa Arbajian, Srinivas Veerla, et al.. (2025). The DNA methylation landscape of primary triple-negative breast cancer. Nature Communications. 16(1). 3041–3041. 7 indexed citations
4.
Staaf, Johan, et al.. (2023). Molecular characteristics of lung adenocarcinoma with respect to patient age at diagnosis. International Journal of Cancer. 153(1). 197–209. 3 indexed citations
5.
Arbajian, Elsa, Mattias Aine, Anna Karlsson, et al.. (2020). Methylation Patterns and Chromatin Accessibility in Neuroendocrine Lung Cancer. Cancers. 12(8). 2003–2003. 4 indexed citations
6.
Arbajian, Elsa, Jakob Hofvander, Linda Magnusson, & Fredrik Mertens. (2020). Deep sequencing of myxoinflammatory fibroblastic sarcoma. Genes Chromosomes and Cancer. 59(5). 309–317. 20 indexed citations
7.
Puls, Florian, Abbas Agaimy, Uta Flucke, et al.. (2020). Recurrent Fusions Between YAP1 and KMT2A in Morphologically Distinct Neoplasms Within the Spectrum of Low-grade Fibromyxoid Sarcoma and Sclerosing Epithelioid Fibrosarcoma. The American Journal of Surgical Pathology. 44(5). 594–606. 58 indexed citations
9.
Puls, Florian, Bo Wängberg, Henrik Fagman, et al.. (2019). Gene fusion involving the insulin‐like growth factor 1 receptor in an ALK‐negative inflammatory myofibroblastic tumour. Histopathology. 74(7). 1098–1102. 21 indexed citations
10.
Al‐Ibraheemi, Alyaa, Andrew L. Folpe, Antonio R. Pérez‐Atayde, et al.. (2018). Aberrant receptor tyrosine kinase signaling in lipofibromatosis: a clinicopathological and molecular genetic study of 20 cases. Modern Pathology. 32(3). 423–434. 48 indexed citations
11.
Arbajian, Elsa, Florian Puls, Cristina R. Antonescu, et al.. (2017). In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets. Clinical Cancer Research. 23(23). 7426–7434. 65 indexed citations
12.
Bekers, Elise M., Patricia J.T.A. Groenen, Marian Verdijk, et al.. (2017). Soft tissue angiofibroma: Clinicopathologic, immunohistochemical and molecular analysis of 14 cases. Genes Chromosomes and Cancer. 56(10). 750–757. 36 indexed citations
13.
Arbajian, Elsa, Jan De Koster, Fredrik Vult von Steyern, & Fredrik Mertens. (2017). Inflammatory leiomyosarcoma is a distinct tumor characterized by near-haploidization, few somatic mutations, and a primitive myogenic gene expression signature. Modern Pathology. 31(1). 93–100. 35 indexed citations
14.
Mandahl, Nils, Linda Magnusson, Jenny Nilsson, et al.. (2017). Scattered genomic amplification in dedifferentiated liposarcoma. Molecular Cytogenetics. 10(1). 25–25. 14 indexed citations
15.
Hofvander, Jakob, Elsa Arbajian, Karin G. Stenkula, et al.. (2017). Frequent low‐level mutations of protein kinase D2 in angiolipoma. The Journal of Pathology. 241(5). 578–582. 18 indexed citations
16.
Arbajian, Elsa, Florian Puls, Linda Magnusson, et al.. (2014). Recurrent EWSR1-CREB3L1 Gene Fusions in Sclerosing Epithelioid Fibrosarcoma. The American Journal of Surgical Pathology. 38(6). 801–808. 106 indexed citations
17.
Puls, Florian, Elsa Arbajian, Linda Magnusson, et al.. (2014). Myoepithelioma of bone with a novelFUS‐POU5F1fusion gene. Histopathology. 65(6). 917–922. 24 indexed citations
18.
Nord, Karolin H., Jenny Nilsson, Elsa Arbajian, et al.. (2013). Recurrent Chromosome 22 Deletions in Osteoblastoma Affect Inhibitors of the Wnt/Beta-Catenin Signaling Pathway. PLoS ONE. 8(11). e80725–e80725. 24 indexed citations
19.
Arbajian, Elsa, Linda Magnusson, Otte Brosjö, et al.. (2013). A Benign Vascular Tumor With a New Fusion Gene. The American Journal of Surgical Pathology. 37(4). 613–616. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026